Objectives: This study aimed to identify potential blood-derived biomarkers distinguishing patients with ankylosing spondylitis from those with mechanical low back pain.
A nkylosing spondylitis (AS) is a chronic inflammatory arthritis predominantly affecting the axial skeleton. 1 A major symptom of this disease is low back pain. However, because low back pain is a common symptom among patients suffering from spondyloarthropathy (SpA) family and rheumatology practices, it is important to mention that diagnosis of AS cannot be based on this symptom alone. 2 To a certain extent, the low back pain of AS can be distinguished from other causes because in AS, the onset of back pain is usually insidious; comes at an early age; is associated with morning stiffness; wakes patients up from sleep in the second half of the night; and improves with exercise but not with rest. This type of low back pain is known as ''inflammatory low back pain,'' whereas pain from other causes is denoted as ''mechanical low back pain.'' [2] [3] [4] However, only 5% of the patients suffering low back pain meet the criteria for AS. 5, 6 In addition, specialized clinical and imaging evaluations made by rheumatologists are required to improve the accuracy of the diagnosis. 7, 8 The accuracy of diagnosis by nonspecialists would be much higher if there were useful blood-derived biomarkers. Although frequently used, acute phase reactants have been found to have low sensitivity and specificity when used alone. 9 Currently, the most useful blood-derived biomarker is HLA-B27. It is present in more than 90% of AS patients of most ethnicities. 10 However, because it is also present in 6% to 9% of most normal populations, the combination of having inflammatory low back pain and HLA-B27 raises the probability of AS to only about 11% to 40%. biomarkers are needed to evaluate the clinical activity of AS. 11 Several studies have been published in attempts to identify specific blood-derived biomarkers for AS. 11 Unfortunately, almost all of these studies compare AS patients against healthy individuals rather than patients with mechanical low back pain. To our knowledge, this paper is one of the first that aimed at comparing a number of both arthritis-related, blood-derived candidate biomarkers in an attempt to distinguish AS from mechanical low back pain patients.
We adopted a 2-stage strategy, based on the premise that most blood-derived biomarkers probably originate at the local inflammation as joint and enthesis. In the first stage, we collected both serum and synovial fluid samples from patients suffering from SpA, including AS, undifferentiated spondyloarthritis (USpA), and reactive arthritis (ReA), and, as a comparison, also rheumatoid arthritis (RA). We tested these samples by using the enzyme-linked immunosorbent assay (ELISA) test for 13 biomarker candidates and identified 4 of them, which showed higher levels in the synovial fluid compared with the serum samples. The tests for these 4 biomarker candidates were then conducted in a second, larger cohort of AS patients and compared with patients having mechanical low back pain as well as healthy individuals. We identified serum monocyte chemotactic protein-1 (MCP-1) as a promising candidate biomarker, meriting inclusion in future multicenter biomarker studies.
MATERIALS AND METHODS

Demographics
Two cohorts of patients participated in the study. The first cohort consisted of the following patients: 10 USpA, 16 ReA, 10 AS, and 12 RA patients. The diagnoses of USpA and ReA were based on the European Spondyloarthropathy Study Group Criteria. 12 All ReA patients developed arthritis within 1 month of an episode of diarrhea. The diagnosis of AS was based on the modified New York Classification Criteria, 13 whereas the diagnosis of RA was based on the American College of Rheumatology Classification Criteria.
14 All patients were considered by their clinicians to have an active form of the disease. In the case of SpA, the ''Ankylosing Spondylitis Disease Activity Index'' (BASDAI) exceeded 4.0 (0-10 scale). 15 The characteristics of these patients are shown in Table 1 . The following numbers of patients in this cohort provided both serum and knee synovial fluid samples: 7 USpA, 13 ReA, 2 AS, and 12 RA patients. All patients were on nonsteroidal anti-inflammatory drugs. The majority of the SpA patients was on sulfasalazine, whereas most of the RA patients were on methotrexate. None of the patients were on biologics or corticosteroids.
For a more precise evaluation, serum samples were collected from a second cohort of 35 male and 15 female AS patients for whom detailed clinical evaluations were available. None of these AS patients were on biologics. One patient each was on methotrexate or prednisone at 5 mg/d, whereas 34 were being treated with sulfasalazine. These medications were prescribed even though there was no peripheral joint or enthesitis swelling. All 50 AS patients satisfied the Modified New York Classification Criteria for AS, and showed radiologic sacroiliitis. 13 The expression of HLA-B27 was tested in 47 of these patients and was positive in all of them. The mean and standard deviation (SD) of the AS patients' age was 35.5 ± 14 years. The mean values and (SDs) for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 17.2 ± 12 mm/h and 7.6 ± 6.2 mg/L, respectively. The means (and SDs) of the clinical scores were the following: spinal pain 4.0 ± 2.7, BASDAI 3.5 ± 2.1 and BASFI 1.8 ± 2.1, all on a scale of 0 to 10. 15, 16 The means (and SDs) of the clinical metrology measurements 17 were as follows: modified Schober, 4.2 ± 3.3 cm; chest expansion, 3.9 ± 2.4 cm; and occiput-to-wall distance, 1.3 ± 3.8 cm. Knee and/or heel swelling was observed in 12 patients.
Twenty-seven patients, 12 male and 15 female, with chronic mechanical lower back pain were recruited from the orthopedic clinic after review by the rheumatologists. All mechanical lower back pain patients satisfied 2 entry criteria. First, based on global clinical evaluation, they were diagnosed by both an orthopedic surgeon and a rheumatologist as not having AS, but mechanical low back pain instead. Second, all of these patients had a history of episodes of pain in the dermatome distribution typical of sciatica. 18 The pain was restricted to 1 side in 21 of these patients and appeared on alternate sides in the other 6. There was no radiologic sacroiliitis in any of these mechanical low back pain patients. In addition, the diagnosis of sciatica was verified in 19 of these 27 patients by magnetic resonance imaging or computed tomography of the lumbar spine or nerve conduction in the lower extremities. The means (and SDs) of patient age, age at onset of pain, and duration of pain were 57.9 ± 11.0 Serum samples were also collected from 39 female and 14 male volunteers, all of whom were apparently healthy and exhibited no chronic low back pain. The mean (and SD) of their age was 29 ± 5.9 years. This project was approved by the Human Protection Committees of the participating institutions.
ELISA
Serum and knee synovial fluid samples were stored at À 801C. The levels of interleukin (IL)-6, IL-8, MCP-1, and tumor necrosis factor (TNF)-a (BD Biosciences), IL-1a, IL-17, IL-23, macrophage inflammatory protein (MIP)-1a, MIP-1b, metalloproteinase (MMP-3), and bone morphogenetic protein 7 (BMP-7) (R&D Systems), and IFN-a and IFN-b (PBL Biomedical Laboratories) were determined by sandwich ELISA using paired antibodies according to the manufacturers' recommendations. The lower limit of detection for all cytokines was 10 pg/mL. Serum and synovial fluid samples were routinely tested in duplicate. The values of each cytokine in a given group of patients were expressed as the means ± SD in pg/mL.
Statistical Analysis
Degrees of statistical difference were evaluated by the Mann-Whitney U test. The P values that were shown were not corrected for multiple testing. Diagnostic usefulness was evaluated by the receiver operator characteristic curve (ROC), as well as likelihood and predictive values (Medcalc). The samples derived from the first and second cohorts were assayed on different days. To avoid technical inconsistency, no attempt was made to normalize the data to compare results between the 2 cohorts. Instead, comparisons were made only between samples assayed on the same days.
RESULTS
Screening for Cytokine Biomarkers Differentially Expressed in Serum and Synovial Fluid
Serum and synovial fluid samples collected from our first cohort of 36 SpA and 12 RA patients (Table 1) only 4 of these candidate biomarkers were significantly higher in the synovial fluid compared with the serum samples, having P values ranging from 0.013 to 0.0000007. As shown in Figure 1 , levels of IL-6 and IL-8 were higher in the synovial fluid samples of both SpA and RA patients. The level of MMP-3 was higher in the synovial fluid samples of SpA patients, whereas the level of MCP-1 was higher in the synovial fluid of RA patients. As we have observed earlier that MCP-1 transcripts are expressed at a high level in synovial tissue samples of SpA patients, 19 serum MCP-1 was included as a potential candidate biomarker in the subsequent analysis.
Levels of IL-6, IL-8, MMP-3, and MCP-1 in a Second Cohort of 50 AS Patients and 27 Patients With Mechanical Low Back Pain
We next measured the levels of IL-6, IL8, MMP-3, and MCP-1 in the serum samples of the following patients: a second cohort of 50 AS patients, 27 patients with mechanical low back pain, and 53 healthy individuals (Fig. 2) . Serum MIP-1a levels were also assessed in comparison. The results for MCP-1 were the most remarkable in that the mean level in AS patients was statistically different than the mean level in patients suffering from mechanical low back pain (P = 5.7E-13) as well as healthy individuals (P = 7.1E-12). As there were more male patients in the AS group compared with the mechanical low back pain group or the group of healthy control individuals, a comparison of MCP-1 levels was also made among the male patients of these 3 groups. The MCP-1 levels of male AS patients were still higher than those with mechanical low back pain (P = 1.7E-14) or healthy controls (P = 3.9E-07). For the male patients, the mean age of the AS group was not statistically different from that of the male healthy controls (P = 0.62).
We then performed a correlation matrix to test whether there was a statistical relationship between serum MCP-1 level and any of the following clinical parameters: sex, age, ESR, CRP, BASDAI, ''Bath Ankylosing Spondylitis Functional Index'' (BASFI), Schober test, occiputto-wall distance, chest expansion, finger-to-floor distance, and the extent of left lateral flexion of the lumbar spine. There was no correlation of the MCP-1 level with any of these parameters, including ESR and CRP (r<0.4). There was also no relationship between the MCP-1 level and knee and/or heel swelling.
Finally, we used the ROC curve to evaluate the usefulness of MCP-1 as a diagnostic tool to distinguish AS patients from patients with mechanical low back pain. 20 Using a cutoff of 154.4 pg/mL, the sensitivity and specificity were 96% and 83.3%, respectively; the area under the curve (AUC) was 0.91 confidence interval of 95%: 0.83 to 0.97, P = 0.0001; and the positive and negative likelihood ratios were 5.76 and 0.048, respectively (Fig. 3) . Assuming that in the general practice, 5% of the patients complaining of chronic low back pain suffer from AS, the positive and negative predictive values were 99.1% and 52.3%, respectively. These statistical values were based on the comparison between AS patients and patients with mechanical low back pain. The statistical values were very similar when AS patients were compared with healthy controls.
We also evaluated the usefulness of HLA-B27 testing in distinguishing patients with AS from our cohort of patients with mechanical low back pain. When tested with ROC, the sensitivity and specificity of this test were 100% and 84.2%, respectively; the AUC was 0.92 (P = 0.0001); and the positive likelihood ratio was 6.33. Assuming a pretest probability of 5% in distinguishing AS from mechanical lower back pain, the post-test probability of AS for those having both positive HLA-B27 and high serum MCP-1 was 65.8%. However, if the patients also provided positive answers to questions of inflammatory back pain, in which the pretest probability of AS was 15%, positive tests for both MCP-1 and HLA-B27 raised the post-test probability of AS to 86.6%. Finally, because CRP is frequently used in the clinics, we also assessed the usefulness of CRP in the diagnosis of our cohort. The AUC was very low at 0.69.
DISCUSSION
Chronic mechanical low back pain patients make up a heterogeneous group ranging from those with completely normal spinal and neurologic images to those with severe noninflammatory pathologies. 6 This report compares blood-derived biomarkers that may help distinguish AS patients from normal participants and patients with chronic mechanical low back pain. Specifically, we focused on patients who had clinically been diagnosed as having mechanical lower back pain and a history of episodes of pain (characteristic of sciatica) by both orthopedic surgeons and rheumatologists. In more than half of the patients with mechanical low back pain, the attending physicians requested magnetic resonance imaging, computed tomography, or nerve conduction studies that verified the diagnosis of sciatica. None of these patients showed sacroiliitis on imaging. The duration of pain was more than 3 months, and their ages of onset, for all except 2 patients, were Z45 years. When submitted to a questionnaire consisting of 3 questions as described in the Materials and Methods section of this study (in which patients addressed whether the quality of the pain had the same characteristics as inflammatory back pain), most of the responding patients gave positive answers to, at most, 2 questions. By incorporating these findings, it was very unlikely that any of these mechanical low back pain patients were misdiagnosed and actually had AS instead. For the AS patients, we recruited a group of patients that satisfied the Modified New York Criteria for AS. 13 All patients were positive for HLA-B27 and showed sacroiliitis on x-ray. Thus, these were classic AS patients.
On the basis of our initial ELISA screening results derived from synovial fluid samples, the serum samples of the AS and mechanical low back pain patients were tested by ELISA for 4 candidate biomarkers. We observed that the mean serum MCP-1 levels of AS were different, to a statistically high degree, from patients with mechanical low back pain and from healthy participants. Unlike earlier reports comparing AS to healthy participants, serum IL-6 was not a distinguishing biomarker in our cohorts. 11 Similar to earlier reports comparing AS patients with healthy participants, CRP was a poor biomarker of both sensitivity and specificity. 5 We used several statistical methods to help us evaluate how useful MCP-1 is as a biomarker in practice. Using ROC, we discovered that MCP-1 showed high sensitivity and specificity of 96% and 83.3%, respectively. The positive likelihood ratio was 5.8. However, this assessment did not take into account the prevalence of AS in patients with chronic low back pain in general practice. Inflammatory low back pain has been reported to be present in only 5% of patients with chronic low back pain. On the basis of this information, we discovered that the positive predictive value was high at 99%, but the negative predictive value was low at 52.3%.
The low negative predictive value described above is not too surprising. There was considerable overlap in the serum MCP-1 levels between AS patients and those with mechanical low back pain (Fig. 4) . Currently, there is no laboratory or clinical parameter that is single handedly capable of diagnosing AS with high positive and negative predictive values. In practice, each patient is assigned a degree of probability of having AS based on a combination of clinical, laboratory, and imaging parameters. 7 For practical purposes, in general practice, history and blood tests would be the preferred first steps toward making a diagnosis. From the history, one can decide whether a particular patient has inflammatory low back pain or not. Currently, the most useful blood test is HLA-B27. If a patient has both inflammatory low back pain and HLA-B27, there is about 30% probability that the patient has AS. 6, 8 Our preliminary assessment showed that if these patients also have high serum MCP-1 levels, the probability increased to 86.6%. One possible drawback of our study was that the age and sex distributions of our AS cohort were different from those in the patients with mechanical low back pain and those in the healthy controls. Among the AS patients, 75% were male, versus 44.4% and 26.4% in the groups with mechanical low back pain and healthy controls, respectively. However, sex was probably not an important factor. When the MCP-1 levels of the male patients in all 3 groups were compared, the mean level was still statistically much higher in the AS group. In addition, in the AS cohort, the MCP-1 serum levels did not show a correlation either with age or with sex. Future multicenter studies will be required to determine the usefulness of MCP-1 as a possible biomarker for AS. As a candidate, MCP-1 has the promising advantage of being easily measured by standard, commercially available ELISA assays.
